KAG-308 is a potent selective and orally active agonist of EP4 receptor (a prostaglandin E2 receptor subtype), suppresses colitis and promotes histological mucosal healing, potently inhibits TNF-α production. KAG-308 shows a K i and an EC 50 of 2.57 nM and 17 nM for human EP4 receptor, respectively, more selective over EP1, EP2, EP3 and IP receptor In Vitro KAG-308 is a potent selective and orally active agonist of EP4 receptor, suppresses colitis and promots histological mucosal healing. KAG-308 shows a K i and EC 50 values of 2.57 nM and 17 nM for human EP4 receptor, respectively, more selective over human EP1 (K i , 1410 nM; EC 50 , 1000 nM), EP2 (K i , 1540 nM; EC 50 , 1000 nM), EP3 (K i , 32.4 nM; EC 50 , 160 nM) and IP receptor (K i , 52.9 nM; EC 50 , >10000 nM). KAG-308 also exhibits potent agonist activity for human and mouse EP4 with an EC 50 of 0.15 nM and 1.0 nM, respectively in the dual luciferase reporter assay. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Form:Solid IC50& Target:EC50: 17 nM (Human EP4 receptor), 160 nM (Human EP3 receptor), 1000 nM (Human EP2 receptor), 1000 nM (Human EP2 receptor), Ki: 2.57 nM (Human EP4 receptor), 32.4 nM (Human EP3 receptor), 52.9 nM (Human IP receptor), 1410 nM (Human EP1 receptor), 1540 nM (Human EP2 receptor)